Roivant Sciences News - September 8, 2026
Roivant Reports Positive Phase 2 Trial Data for Mosliciguat, Initiates Phase 3 Study
Roivant Sciences announced positive results from its Phase 2 PHocus clinical trial for mosliciguat in patients with pulmonary hypertension associated with...
🟢 Roivant Sciences is trading 13.46% up today after positive Phase 2 PHocus results
Roivant Sciences is trading 13.46% up now at $39.63 after positive Phase 2 PHocus results for mosliciguat in pulmonary hypertension associated with...
Roivant Surges 21% on Blockbuster Lung Drug Data — But Can a Phase 2 Win Sustain a $7 Billion Bet?
Shares of Roivant Sciences vaulted +21.2% to $42.33 this morning after the company disclosed what it called the strongest efficacy ever recorded in a...
🟢 Roivant Sciences surges 21% in pre-market on positive mosliciguat PHocus topline results
Roivant Sciences is trading at $42.33, up +21.19%, following the announcement of positive Phase 2 PHocus topline results for mosliciguat. The positive results...